Editorial
Pemafibrate: PROMINENT failure or an urgent need for therapeutic replacement?
Pemafibrato: ¿un fracaso PROMINENTe o una necesidad urgente de reposicionamiento terapéutico?
Juan Carlos Laguna Egea
, Núria Roglans Ribas, Roger Bentanachs Raset
Corresponding author
Unitat de Farmacologia, Farmacognòsia i Terapèutica, Departament de Farmacologia, Toxicologia i Química Terapèutica, Facultatde Farmàcia i Ciències de la Alimentació, Centro de Investigación Biomédica en Red, Fisiopatología y Nutrición de la Obesidad (CIBEROBN), Instituto de Biomedicina de la UB (IBUB), Barcelona, Spain
Read
342
Timeswas read the article
151
Total PDF
191
Total HTML
Share statistics
array:24 [ "pii" => "S2529912323000487" "issn" => "25299123" "doi" => "10.1016/j.artere.2023.07.004" "estado" => "S300" "fechaPublicacion" => "2023-07-01" "aid" => "678" "copyright" => "The Authors" "copyrightAnyo" => "2023" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Clin Investig Arterioscler. 2023;35:202-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0214916823000451" "issn" => "02149168" "doi" => "10.1016/j.arteri.2023.05.001" "estado" => "S300" "fechaPublicacion" => "2023-07-01" "aid" => "678" "copyright" => "The Authors" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Clin Invest Arterioscl. 2023;35:202-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">EDITORIAL</span>" "titulo" => "Pemafibrato: ¿un fracaso PROMINENTe o una necesidad urgente de reposicionamiento terapéutico?" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "202" "paginaFinal" => "205" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Pemafibrate: PROMINENT failure or an urgent need for therapeutic replacement?" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2961 "Ancho" => 1675 "Tamanyo" => 277161 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A. Ligando clásico del receptor PPARα: ambos ligandos (fenofibrato y gemfibrozilo) reclutan los mismos coactivadores de transcripción y producen efectos similares. B. Modulador del receptor PPARα: pemafibrato comparte coactivadores con el ligando clásico (fenofibrato), pero recluta también coactivadores diferentes, presentando así un perfil de eficacia y seguridad diferenciado del fenofibrato.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Juan Carlos Laguna Egea, Núria Roglans Ribas, Roger Bentanachs Raset" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Juan Carlos" "apellidos" => "Laguna Egea" ] 1 => array:2 [ "nombre" => "Núria" "apellidos" => "Roglans Ribas" ] 2 => array:2 [ "nombre" => "Roger" "apellidos" => "Bentanachs Raset" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2529912323000487" "doi" => "10.1016/j.artere.2023.07.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912323000487?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916823000451?idApp=UINPBA00004N" "url" => "/02149168/0000003500000004/v1_202308020950/S0214916823000451/v1_202308020950/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2529912323000499" "issn" => "25299123" "doi" => "10.1016/j.artere.2023.07.005" "estado" => "S300" "fechaPublicacion" => "2023-07-01" "aid" => "670" "copyright" => "Sociedad Española de Arteriosclerosis" "documento" => "article" "crossmark" => 1 "subdocumento" => "rev" "cita" => "Clin Investig Arterioscler. 2023;35:206-17" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Review article</span>" "titulo" => "Remnant cholesterol, vascular risk, and prevention of atherosclerosis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "206" "paginaFinal" => "217" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1728 "Ancho" => 3341 "Tamanyo" => 334757 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Modified from Ginsberg et al.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a></p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán" "autores" => array:5 [ 0 => array:2 [ "nombre" => "Xavier" "apellidos" => "Pintó" ] 1 => array:2 [ "nombre" => "Marta" "apellidos" => "Fanlo" ] 2 => array:2 [ "nombre" => "Virginia" "apellidos" => "Esteve" ] 3 => array:2 [ "nombre" => "Jesús" "apellidos" => "Millán" ] 4 => array:1 [ "colaborador" => "on behalf of the Atherogenic Dyslipidemia Working Group, Spanish Society of Arteriosclerosis (SEA)" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0214916823000086" "doi" => "10.1016/j.arteri.2023.02.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0214916823000086?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912323000499?idApp=UINPBA00004N" "url" => "/25299123/0000003500000004/v3_202311141613/S2529912323000499/v3_202311141613/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "S2529912323000554" "issn" => "25299123" "doi" => "10.1016/j.artere.2023.07.007" "estado" => "S300" "fechaPublicacion" => "2023-07-01" "aid" => "684" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Clin Investig Arterioscler. 2023;35:201" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Clínica e Investigación en Arteriosclerosis has been assigned an impact factor: A goal achieved!" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "201" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "La asignación de factor impacto a Clínica e Investigación en Arteriosclerosis: ¡Un objetivo conseguido!" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Josep Ribalta, Carlos Lahoz, Xavier Pintó" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Josep" "apellidos" => "Ribalta" ] 1 => array:2 [ "nombre" => "Carlos" "apellidos" => "Lahoz" ] 2 => array:2 [ "nombre" => "Xavier" "apellidos" => "Pintó" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912323000554?idApp=UINPBA00004N" "url" => "/25299123/0000003500000004/v3_202311141613/S2529912323000554/v3_202311141613/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Editorial</span>" "titulo" => "Pemafibrate: PROMINENT failure or an urgent need for therapeutic replacement?" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "202" "paginaFinal" => "205" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Juan Carlos Laguna Egea, Núria Roglans Ribas, Roger Bentanachs Raset" "autores" => array:3 [ 0 => array:4 [ "nombre" => "Juan Carlos" "apellidos" => "Laguna Egea" "email" => array:1 [ 0 => "jclagunae@ub.edu" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "Núria" "apellidos" => "Roglans Ribas" ] 2 => array:2 [ "nombre" => "Roger" "apellidos" => "Bentanachs Raset" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Unitat de Farmacologia, Farmacognòsia i Terapèutica, Departament de Farmacologia, Toxicologia i Química Terapèutica, Facultatde Farmàcia i Ciències de la Alimentació, Centro de Investigación Biomédica en Red, Fisiopatología y Nutrición de la Obesidad (CIBEROBN), Instituto de Biomedicina de la UB (IBUB), Barcelona, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Pemafibrato: ¿un fracaso PROMINENTe o una necesidad urgente de reposicionamiento terapéutico?" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2961 "Ancho" => 1675 "Tamanyo" => 285456 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A. Classical PPARα receptor ligand: both ligands (fenofibrate and gemfibrozil) recruit the same transcription co-activators and produce similar effects. B. PPARα receptor modulator: pemafibrate shares coactivators with the classical ligand (fenofibrate), but also recruits different coactivators, thus presenting a different efficacy and safety profile to fenofibrate.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Background</span><p id="par0005" class="elsevierStylePara elsevierViewall">Over time, interest in fibrates has gone hand in hand with scientific evidence of the role of triglyceride-rich lipoproteins in the development of atherosclerosis and related cardiovascular disease. Although there is no doubt that statin therapy has brought about a reduction in cardiovascular risk, it is at most 30%–35%, leaving a remaining cardiovascular risk of 70% in statin-treated patients, not directly related to LDL-cholesterol (LDL-C), without adequate control. If we exclude the particular case of lipoprotein(a) [Lp(a)], this segment would include two other lipid risk factors, hypertriglyceridaemia and low HDL cholesterol (HDL-C) concentrations, often associated with metabolic syndrome or type 2 diabetes mellitus (T2DM). To date, from the point of view of cardiovascular risk reduction, pharmacological measures aimed at increasing HDL-C have been ineffective, as demonstrated by the failure of cholesteryl ester transfer protein (CETP) inhibitors. Consequently, control of hypertriglyceridaemia remains a possible intervention to reduce cardiovascular risk in statin-treated patients,<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> hence the renewed interest in fibrates.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Why are plasma triglycerides a cardiovascular risk factor?</span><p id="par0010" class="elsevierStylePara elsevierViewall">Plasma triglycerides are transported in lipoproteins that contain, as a structural apolipoprotein, apolipoprotein B, apo B-100 when the origin is hepatic (VLDL), in fasting situations, or apo B-48, when the origin is intestinal (chylomicrons), in postprandial situations. Both chylomicrons and nascent VLDL are too large to be incorporated into the subendothelial space of the arterial system. However, both types of lipoproteins are extensively remodelled during their stay in the blood compartment by lipolytic processes that deliver fatty acids to various tissues, such as skeletal muscle and adipose. During these processes, they are transformed into intermediate or remnant lipoproteins, changing their apolipoprotein content and lipid composition, proportionally reducing their triglyceride content, and enriching their cholesterol content, finally giving rise, in the case of VLDL, to LDL lipoproteins, which contain only apo B-100. These changes mean that the remaining lipoproteins have high atherogenic potential, due to a series of characteristics, such as a smaller size and a higher cholesterol content, and because the fatty acids present in the remaining lipoprotein triglycerides, and their derivatives by enzymatic modification, redox processes, etc., have the capacity to promote chronic low-intensity inflammatory processes that favour the development of atheromatous plaque.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2–4</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Fibrates and hypertriglyceridaemia</span><p id="par0015" class="elsevierStylePara elsevierViewall">Together with ion exchange resins, fibrates constitute one of the first therapeutic groups used in the management of dyslipidaemia. Although they favourably modify concentrations of the three major lipoproteins (VLDL, LDL, and HDL), their most marked effect lies in the reduction of plasma triglycerides, which is why they have traditionally been used in the treatment of hypertriglyceridaemia and mixed or atherogenic dyslipidaemia, typical of diabetics. The three most commonly used fibrates are gemfibrozil, bezafibrate, and fenofibrate. In the pre-statin era, gemfibrozil demonstrated a reduction in the risk of cardiovascular events, both in primary and secondary prevention, but its use has declined because its administration in combination with statins alters the metabolism of statins (especially simvastatin), increasing the occurrence of adverse reactions associated with skeletal muscle toxicity. Bezafibrate and fenofibrate have not been widely used in the statin era to manage dyslipidaemia for two basic reasons:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">□</span><p id="par0020" class="elsevierStylePara elsevierViewall">Lack of efficacy in reducing cardiovascular accidents when used in combination with statins.</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">□</span><p id="par0025" class="elsevierStylePara elsevierViewall">The impaired safety profile of the statin-fibrate combination, due to potential hepatic and renal adverse effects associated with the use of fibrates.</p></li></ul></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Pemafibrate and PROMINENT study</span><p id="par0030" class="elsevierStylePara elsevierViewall">Fibrates act as selective ligands of a type II nuclear receptor (transcription factors activated by binding to specific ligands), the peroxisome proliferator-activated receptor alpha or PPARα. Among the traditional fibrates, gemfibrozil and fenofibrate primarily have an affinity for PPARα, while bezafibrate has a similar affinity for all three PPAR isoforms, α, β, and γ. Binding of the ligand to the PPARα receptor promotes its activity, increasing:<ul class="elsevierStyleList" id="lis0010"><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">□</span><p id="par0035" class="elsevierStylePara elsevierViewall">The transactivation activity of genes with a PPAR-responsive element in their promoter area, such as <span class="elsevierStyleItalic">APOAI</span>, <span class="elsevierStyleItalic">APOAV</span>, <span class="elsevierStyleItalic">LPL</span>, <span class="elsevierStyleItalic">ACO,</span> or <span class="elsevierStyleItalic">CPTI</span>, increasing lipolytic activity on plasma lipoproteins and fatty acid catabolism in the liver.</p></li><li class="elsevierStyleListItem" id="lsti0020"><span class="elsevierStyleLabel">□</span><p id="par0040" class="elsevierStylePara elsevierViewall">Transrepression activity on pro-inflammatory transcription factors, such as NFκB or AP-1, thus reducing the low-intensity inflammatory processes associated with the chronic alterations in energy metabolism present in metabolic syndrome.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a></p></li></ul></p><p id="par0045" class="elsevierStylePara elsevierViewall">Although, as already indicated, fibrates have not shown a reduction in cardiovascular events in association with statins, the specific study of subgroups of patients included in the FIELD and ACCORD trials, in which fenofibrate was used, indicate a possible significant reduction in patients with high triglyceride and low HDL-C levels, a situation known as atherogenic dyslipaemia, characteristic of patients with T2DM or metabolic syndrome.<a class="elsevierStyleCrossRefs" href="#bib0030"><span class="elsevierStyleSup">6,7</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">Over the last decade, a new fibrate, pemafibrate, has been developed that has a high affinity for the PPARα receptor, a strong hypotriglyceridemic effect, and a good safety profile, which has led to its approval by the Japanese health authorities for the control of dyslipidaemia in combination with statins. Pemafibrate, which is excreted via the biliary route, unlike fenofibrate, which is mostly excreted in the urine, has been classified as a selective modulator of the PPARα receptor, compared to classical ligands such as fenofibrate.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> Due to its specific molecular interaction with the ligand binding site or LBD of PPARα, it favours its association with a transcriptional coactivator protein complex that enhances the expression of the genes responsible for the lipid-lowering effect, while reducing the intensity of the adverse hepatic and renal effects typical of fibrates. Unlike fenofibrate, pemafibrate induces in human hepatocytes, in a PPARα-dependent manner, the expression of genes such as <span class="elsevierStyleItalic">ACO, VLDLR, FGF21</span>, or <span class="elsevierStyleItalic">ABCA1</span>, positively modulating lipid metabolism (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0055" class="elsevierStylePara elsevierViewall">These particular characteristics of pemafibrate have led to its clinical use being associated with a clear improvement in the efficacy/risk ratio compared to traditional fibrates, especially fenofibrate, leading to the development of the PROMINENT clinical trial,<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> the intention of which was to verify the possible effect of pemafibrate in reducing cardiovascular risk in diabetic patients. PROMINENT is a randomised, double-blind, multinational clinical trial involving more than 10,000 patients with T2DM who had hypertriglyceridaemia (200–499 mg/dL) and HDL-C ≤ 40 mg/dL, mostly treated with statins and with LDL-C ≤ 80 mg/dL. The primary endpoint of the trial was the aggregate incidence of myocardial infarction, ischaemic stroke, coronary revascularisation, and cardiovascular death. During the 3.4 years of mean follow-up, pemafibrate treatment did not reduce the primary endpoint compared to the placebo group, despite inducing a marked reduction in triglycerides, cholesterol contained in VLDL and remnant lipoproteins, and circulating apo C-III. In contrast to the clinical trials conducted in the authorisation process for pemafibrate (in which it was not associated with statins), the PROMINENT study detected a modest but significant increase in apo B (4.8%) and LDL-C (12.3%) concentrations in patients treated with pemafibrate compared to the placebo group, suggesting that the lipolytic capacity to convert VLDL to LDL, increased by pemafibrate, would exceed the hepatic LDL clearance capacity in these patients. In this regard, the results of a phase III trial comparing the effect of pemafibrate at two doses, .2 and .4 mg/day, compared to fenofibrate (107 mg/day) are interesting. Although pemafibrate, at both doses, showed a superior hypotriglyceridemic effect to fenofibrate, at the .4 mg/day dose (the dose used in the PROMINENT study), it increased LDL-C levels by 4% (p = .054) over the fenofibrate group.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">10</span></a> The results of the PROMINENT trial, published in November 2022,<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> dealt a severe blow to the theory of vascular risk associated with triglyceride-rich lipoproteins and the possible use of pemafibrate to reduce it in patients already treated with statins. Given that LDL-C concentration is the main cardiovascular risk factor, the increase in LDL-C values observed in the PROMINENT trial could have been sufficient to negate the potential beneficial effects of the reduction in plasma triglyceride concentration, remnant lipoproteins or anti-inflammatory activity associated with pemafibrate treatment. In this regard, it should be noted that in the ACCORD study, in which, as in the PROMINENT study, the patients included were mostly treated with statins, the additional use of fenofibrate (initial dose of 160 mg/day) did not lead to any significant change in LDL-C concentration compared to the placebo group (reductions from 100.0 to 81.1 mg/dL in the fenofibrate group and from 101.1 to 80.0 mg/dL in the placebo group at the end of the study).</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Pemafibrate: forget or reposition?</span><p id="par0060" class="elsevierStylePara elsevierViewall">A cursory analysis of the results of the PROMINENT study would indicate that pemafibrate might be destined for the list of new therapies in cardiovascular prevention that did not live up to expectations, headed by the CETP inhibitors. However, closer scrutiny indicates that the use of pemafibrate, despite the slight increase in LDL-C levels, does not significantly increase cardiovascular risk, nor does it worsen the overall incidence of adverse effects compared to placebo. Although the results of the PROMINENT study suggest no difference in renal toxicity and venous thrombosis incidence compared to fenofibrate, pemafibrate does significantly improve hepatic safety, significantly reducing the total number of hepatic adverse events. Pemafibrate did not increase transaminase levels compared to placebo and, in fact, significantly reduced the incidence of non-alcoholic fatty liver disease (NAFLD) by 22%. The latter effect is of paramount importance for two reasons:</p><p id="par0065" class="elsevierStylePara elsevierViewall">According to a recent study, NAFLD has a prevalence of 32.4% worldwide and is on the rise.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> It should be emphasised that, to date, NAFLD has no approved pharmacological treatment and is the gateway to the future development of cirrhosis and hepatocellular carcinoma, diseases that both have a difficult prognosis.</p><p id="par0070" class="elsevierStylePara elsevierViewall">NAFLD is now considered a cardiovascular risk factor, because it is associated with increased cardiovascular morbidity and mortality.<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12,13</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">Recently, Nakajima et al. reported the results of a phase II trial in patients with steatohepatitis (118 patients), in which pemafibrate treatment reduced liver stiffness, as assessed by magnetic resonance elastography, and blood levels of LDL-C and ALT vs. placebo.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> The repositioning of pemafibrate to treat NAFLD could not only be an effective therapy for NAFLD, but could also help reduce cardiovascular risk in NAFLD patients.</p><p id="par0080" class="elsevierStylePara elsevierViewall">Although approximately 50% of patients with obesity and/or T2DM are considered to have NAFLD, this does not seem to be the case for the patients participating in the PROMINENT study (200 cases in more than 5000 patients included in the placebo group, prevalence less than 5%), because patients with liver disease with clinical symptoms were in fact excluded from the study. It remains to be seen what the outcome of the PROMINENT study would have been if NAFLD had been included as an inclusion criterion.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Funding</span><p id="par0085" class="elsevierStylePara elsevierViewall">Funding was obtained from grant <span class="elsevierStyleGrantNumber" refid="gs0005">PID2020-112870RB-I00</span> from <span class="elsevierStyleGrantSponsor" id="gs0005">MCIN/AEI/10.13039/501100011033</span>, grant <span class="elsevierStyleGrantNumber" refid="gs0010">2021 SGR 00345</span> from the <span class="elsevierStyleGrantSponsor" id="gs0010">Generalitat de Catalunya</span>, there is a basic research grant 2020 from the <span class="elsevierStyleGrantSponsor" id="gs0015">SEA</span>. R.B is a pre-doctoral student PREDOCS-UB.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Conflict of interests</span><p id="par0090" class="elsevierStylePara elsevierViewall">The authors have no conflict of interests to declare.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:8 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Background" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Why are plasma triglycerides a cardiovascular risk factor?" ] 2 => array:2 [ "identificador" => "sec0015" "titulo" => "Fibrates and hypertriglyceridaemia" ] 3 => array:2 [ "identificador" => "sec0020" "titulo" => "Pemafibrate and PROMINENT study" ] 4 => array:2 [ "identificador" => "sec0025" "titulo" => "Pemafibrate: forget or reposition?" ] 5 => array:2 [ "identificador" => "sec0030" "titulo" => "Funding" ] 6 => array:2 [ "identificador" => "sec0035" "titulo" => "Conflict of interests" ] 7 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2961 "Ancho" => 1675 "Tamanyo" => 285456 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A. Classical PPARα receptor ligand: both ligands (fenofibrate and gemfibrozil) recruit the same transcription co-activators and produce similar effects. B. PPARα receptor modulator: pemafibrate shares coactivators with the classical ligand (fenofibrate), but also recruits different coactivators, thus presenting a different efficacy and safety profile to fenofibrate.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:14 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.N. Ginsberg" 1 => "C.J. Packard" 2 => "M.J. Chapman" 3 => "J. Borén" 4 => "C.A. Aguilar-Salinas" 5 => "M. Averna" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/eurheartj/ehab551" "Revista" => array:6 [ "tituloSerie" => "Eur Heart J" "fecha" => "2021" "volumen" => "42" "paginaInicial" => "4791" "paginaFinal" => "4806" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34472586" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "O.P. Ganda" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/mol.0000000000000875" "Revista" => array:6 [ "tituloSerie" => "Curr Opin Lipidol" "fecha" => "2023" "volumen" => "34" "paginaInicial" => "105" "paginaFinal" => "113" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36924359" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "X. Pintó" 1 => "M. Fanlo" 2 => "V. Esteve" 3 => "J. Millán" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.arteri.2023.02.001" "Revista" => array:2 [ "tituloSerie" => "Clín Investig Arterioscler" "fecha" => "2023" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "P.M. Ridker" 1 => "D.L. Bhatt" 2 => "A.D. Pradhan" 3 => "R.J. Glynn" 4 => "J.G. MacFadyen" 5 => "S.E. Nissen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/s0140-6736(23)00215-5" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2023" "volumen" => "401" "paginaInicial" => "1293" "paginaFinal" => "1301" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36893777" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Peroxisome proliferator-activated receptors and the control of inflammation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. Cabrero" 1 => "J.C. Laguna" 2 => "M. Vázquez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2174/1568010023344616" "Revista" => array:4 [ "tituloSerie" => "Curr Drug Targets Inflamm Allergy" "fecha" => "2002" "paginaInicial" => "243" "paginaFinal" => "248" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Jun" 1 => "C. Foote" 2 => "J. Lv" 3 => "B. Neal" 4 => "A. Patel" 5 => "S.J. Nicholls" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(10)60656-3" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2010" "volumen" => "375" "paginaInicial" => "1875" "paginaFinal" => "1884" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20462635" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effects of combination lipid therapy in type 2 diabetes mellitus" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Amarenco" 1 => "J. Bogousslavsky" 2 => "A. Callahan 3rd" 3 => "L.B. Goldstein" 4 => "M. Hennerici" 5 => "A.E. Rudolph" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "N Engl J Med" "fecha" => "2011" "volumen" => "365" "paginaInicial" => "687" "paginaFinal" => "696" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S. Yamashita" 1 => "D. Masuda" 2 => "Y. Matsuzawa" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s11883-020-0823-5" "Revista" => array:5 [ "tituloSerie" => "Curr Atheroscler Rep" "fecha" => "2020" "volumen" => "22" "paginaInicial" => "5" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31974794" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Triglyceride lowering with pemafibrate to reduce cardiovascular risk" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Das Pradhan" 1 => "R.J. Glynn" 2 => "J.-C. Fruchart" 3 => "J.G. MacFadyen" 4 => "E.S. Zaharris" 5 => "B.M. Everett" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/nejmoa2210645" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2022" "volumen" => "387" "paginaInicial" => "1923" "paginaFinal" => "1934" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36342113" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "S. Ishibashi" 1 => "H. Arai" 2 => "K. Yokote" 3 => "E. Araki" 4 => "H. Suganami" 5 => "S. Yamashita" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jacl.2017.10.006" "Revista" => array:6 [ "tituloSerie" => "J Clin Lipidol" "fecha" => "2018" "volumen" => "12" "paginaInicial" => "173" "paginaFinal" => "184" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29203092" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K. Riazi" 1 => "H. Azhari" 2 => "J.H. Charette" 3 => "F.E. Underwood" 4 => "J.A. King" 5 => "E.E. Afshar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2468-1253(22)00165-0" "Revista" => array:5 [ "tituloSerie" => "Lancet Gastroenterol Hepatol" "fecha" => "2022" "volumen" => "7" "paginaInicial" => "851" "paginaFinal" => "861" ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.B. Duell" 1 => "F.K. Welty" 2 => "M. Miller" 3 => "A. Chait" 4 => "G. Hammond" 5 => "Z. Ahmad" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1161/ATV.0000000000000153" "Revista" => array:6 [ "tituloSerie" => "Arterioscler Thromb Vasc Biol" "fecha" => "2022" "volumen" => "42" "paginaInicial" => "e168" "paginaFinal" => "e185" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35418240" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "NAFLD and cardiovascular diseases: a clinical review" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Kasper" 1 => "A. Martin" 2 => "S. Lang" 3 => "F. Kütting" 4 => "T. Goeser" 5 => "M. Demir" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00392-020-01709-7" "Revista" => array:6 [ "tituloSerie" => "Clin Res Cardiol" "fecha" => "2021" "volumen" => "110" "paginaInicial" => "921" "paginaFinal" => "937" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32696080" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Nakajima" 1 => "Y. Eguchi" 2 => "M. Yoneda" 3 => "K. Imajo" 4 => "N. Tamaki" 5 => "H. Suganami" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/apt.16596" "Revista" => array:6 [ "tituloSerie" => "Aliment Pharmacol Ther" "fecha" => "2021" "volumen" => "54" "paginaInicial" => "1263" "paginaFinal" => "1277" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34528723" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/25299123/0000003500000004/v3_202311141613/S2529912323000487/v3_202311141613/en/main.assets" "Apartado" => array:4 [ "identificador" => "96084" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "EDITORIALS" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/25299123/0000003500000004/v3_202311141613/S2529912323000487/v3_202311141613/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529912323000487?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 6 | 8 | 14 |
| 2024 October | 28 | 28 | 56 |
| 2024 September | 67 | 22 | 89 |
| 2024 August | 39 | 33 | 72 |
| 2024 July | 17 | 33 | 50 |
| 2024 June | 20 | 17 | 37 |
| 2024 May | 14 | 10 | 24 |